Clin Geriatr Med 2011年8月号

Clin Geriatr Med 2011年8月号では、サルコペニアの特集が組まれています。下記HPで抄録までは無料で見ることができます。

http://www.geriatric.theclinics.com/issues?issue_key=S0749-0690(11)X0003-4

特に最後の論文（Clinical Trials on Sarcopenia: Methodological Issues Regarding Phase 3 Trials）は、サルコペニアの臨床研究を考える上で参考になると思いますので、抄録をここで紹介しておきます。

Abstract
Phase 3 trials estimate the effectiveness of an intervention to prevent, delay the onset of, or treat sarcopenia. Participants should have sarcopenia or present a sarcopenia risk profile. Control group should be characterized by the best standard of clinical care. This article further develops issues on sarcopenia definition, target population, primary and secondary end points, duration of the trials, muscle mass assessment, strength and physical performance assessment, and control of possible confounders. The challenges to conduct phase 3 trials in the elderly should not offset the opportunities for the development of new strategies to counteract sarcopenia and prevent late-life disability.

目次

Sarcopenia: Origins and Clinical Relevance
Irwin H. Rosenberg 337-339

Toward a Definition of Sarcopenia
Tommy E. Cederholm, Juergen M. Bauer, Yves Boirie, Stephane M. Schneider, et al.　341-353

The Epidemiology of Sarcopenia
Ian Janssen 355-363

Physiopathological Mechanism of Sarcopenia
Stéphane Walrand, Christelle Guillet, Jérome Salles, Noël Cano, et al.　365-385

Consequences of Sarcopenia
Marjolein Visser, Laura A. Schaap 387-399

Sarcopenia and Obesity
Debra L. Waters, Richard N. Baumgartner 401-421

Current and Future Pharmacologic Treatment of Sarcopenia
Yves Rolland, Graziano Onder, John E. Morley, Sophie Gillette-Guyonet, et al.　423-447

Physical Activity and Sarcopenia
Fabien Pillard, Dalila Laoudj-Chenivesse, Gilles Carnac, Jacques Mercier, et al.　449-470

Clinical Trials on Sarcopenia: Methodological Issues Regarding Phase 3 Trials
Gabor Abellan van Kan, Wm. Cameron Chumlea, Sophie Gillette-Guyonet, Mathieu Houles, et al.　471-482